Supernus Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SUPERNUS PHARMS, and what generic alternatives to SUPERNUS PHARMS drugs are available?
SUPERNUS PHARMS has three approved drugs.
There are twenty-five US patents protecting SUPERNUS PHARMS drugs. There is one tentative approval on SUPERNUS PHARMS drugs.
There are forty-six patent family members on SUPERNUS PHARMS drugs in ten countries and two supplementary protection certificates in two countries.
Summary for Supernus Pharms
International Patents: | 46 |
US Patents: | 25 |
Tradenames: | 3 |
Ingredients: | 3 |
NDAs: | 3 |
Drugs and US Patents for Supernus Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-003 | Aug 16, 2013 | AB1 | RX | Yes | No | 9,622,983 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-004 | Aug 16, 2013 | AB1 | RX | Yes | Yes | 8,877,248 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-002 | Oct 19, 2012 | RX | Yes | No | 7,910,131 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-003 | Oct 19, 2012 | RX | Yes | Yes | 9,119,791 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Supernus Pharms | OXTELLAR XR | oxcarbazepine | TABLET, EXTENDED RELEASE;ORAL | 202810-001 | Oct 19, 2012 | RX | Yes | No | 7,722,898 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Supernus Pharms | TROKENDI XR | topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 201635-004 | Aug 16, 2013 | AB1 | RX | Yes | Yes | 8,992,989 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for SUPERNUS PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 200 mg | ➤ Subscribe | 2014-04-03 |
➤ Subscribe | Extended-release Tablets | 150 mg and 300 mg | ➤ Subscribe | 2013-04-12 |
➤ Subscribe | Extended-release Capsules | 25 mg, 50 mg, and 100 mg | ➤ Subscribe | 2014-05-12 |
International Patents for Supernus Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2010028207 | ⤷ Try a Trial |
European Patent Office | 2026815 | ⤷ Try a Trial |
Japan | 6290100 | ⤷ Try a Trial |
Germany | 602007012236 | ⤷ Try a Trial |
European Patent Office | 2359830 | ⤷ Try a Trial |
Canada | 2735934 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Supernus Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2317997 | 2190050-1 | Sweden | ⤷ Try a Trial | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
0138441 | SPC/GB95/028 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.